Compare DexCom, Inc. (DXCM) vs Honest Company Inc (HNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Honest Company Inc — how do they compare? DexCom, Inc. trades at $90.86 (market cap $33.79B), while Honest Company Inc trades at $5.1 (market cap $558.95M). The key difference: DexCom, Inc. is far larger — about 60.5× Honest Company Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Honest Company Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | HNST | |
|---|---|---|
Market Cap | $33.79B | $558.95M |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $5.46 |
52-Week Low | $54.84 | $2.10 |
Enterprise Value | $33.24B | $462.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
HNST trades at $5.065, down 3.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 results with an earnings beat but declining revenue due to strategic exits. Despite negative net income margins and ROE, cash flow improved significantly in 2025 with $14.15M net cash flow. Analyst consensus shows 30% buy ratings amid ongoing profitability challenges.
The outlook remains cautious as strategic exits pressure revenue while cost improvements support margins. Investment opportunity exists if profitability targets are met, but risks include persistent net losses and competitive pressures in personal care markets. The stock's elevated P/E ratio of 48.83 requires careful valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
